The dream of an “off-the-shelf” T-cell therapy has become a reality, courtesy of the allogeneic aficionados over at Atara Biotherapeutics. Monday, the company’s allogeneic Epstein-Barr virus-positive ...

THOUSAND OAKS, Calif., January 21, 2025--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell ...

Atara Biotherapeutics ATRA is a nimble allogeneic T cell immunotherapy company with several near-term catalysts. This Zacks Rank #2 (Buy) company boasts a pipeline of differentiated therapies across a ...

Atara is working closely with its partners and the FDA to lift clinical hold and support EBVALLO™ BLA resubmission in the U.S. Atara remains focused on delivering on the future financial value of ...

Thousand Oaks pharmaceutical Atara Biotherapeutics submits its drug Ebvallo for Food and Drug Administration approval for a second time. Atara Biotherapeutics' headquarters in Thousand Oaks. Thousand ...

Nguyen AnhCo, the President and CEO of Atara Biotherapeutics, Inc. (NASDAQ:ATRA), has reported the sale of 1,664 shares of common stock. The transaction, which took place on November 18, 2024, was ...

Atara Biotherapeutics continues to salami slice its head count, this time laying off 30% of what remains of the biopharma's workforce. Only three months ago, the company waved goodbye to half of its ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop ...

The U.S. Food and Drug Administration (FDA) has accepted the filing of Atara’s Biologics License Application (BLA) for tabelecleucel (tab-cel®) indicated as monotherapy for treatment of adult and ...

When patients undergo transplant procedures, the immunosuppressive drug regimen that prevents rejection of the organ or stem cells can lead to a potentially deadly complication. This week, the ...

THOUSAND OAKS, Calif--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (ATRA) (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...